High-Risk Skin Cancers With Atezolizumab Plus NT-I7

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Publication date: Apr 03, 2019

The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)

Concepts Keywords
Alkaline Phosphatase Dose dexamethasone nausea
Alopecia HIV
ALT Dysfunction
Amputation Hepatitis infection
Amylase Greater myocardial infarction
Antibiotics Tissue archival tumor
Anticoagulation Criteria severe infections
Antifungal Clinically significant hypercalcemia
APTT HBc eligible Hepatitis
Arrhythmia History severe hypersensitivity
AST Cancer
Asymptomatic Eligible controlled diabetes
Bilirubin TB severe infections
Biopsy Equivalent adrenal insufficiency
BRAF Inhibitor Active CNS metastases
Breastfeeding G psoriatic arthritis
Carcinoma Active hepatitis
Cardiovascular Disease Bronchiolitis obliterans
CD4 Rash
Central Nervous System Positive hepatitis
Chemotherapy HCV RNA
Clinical Laboratory Radiation therapy
Concurrent Oral contraceptives
Contraceptive Antibiotics
Cooperative Group Anticancer therapy
Corticosteroids Vaccination
CPI Chemotherapy
Creatinine Radiotherapy
Creatinine Clearance Surgery
Cytological Hormone replacement therapy
Diabetes Mellitus Immunotherapy
Endocrinopathy Kidney transplant
Epidural Herbal therapy
Failure Rate Amputation
Glucose HAART
Growth Factor Investigational therapies
Hemoglobin Dialysis
Hemoglobin A1C Medicine
Heparin Clinical medicine
Herbal Therapy Health
Histologically Cancer treatments
HIV Immune system
HIV Positive Antineoplastic drugs
Hormone Replacement Therapy RTT
Hypercalcemia Bristol-Myers Squibb
Hypersensitivity Ipilimumab
Hypertension Checkpoint inhibitor
IL 15 Radiation therapy
Immunomodulatory Atezolizumab
Immunotherapeutic Radiation
Immunotherapy Antibodies
Informed Consent Transplantation
INR MRI
Investigational Drug Chemotherapy
Ipilimumab Dialysis
Lactation
Leptomeningeal
Lesion
Lipase
Liver
Malignancy
MCC
Melanoma
Metastases
Metastasis
Metastatic
Metastatic Tumor
Mitomycin
Molecular Weight
Monoclonal Antibodies
MRI
Myocardial Infarction
Nave
Nerve
Neuropathy
Opportunistic Infections
Oral Contraceptives
Organ
Pain
Palliative
PCR
Physical Examination
Physician
Platelets
Polymerase Chain Reaction
Pregnancy Test
Radiation Therapy
Radiographic
Radiotherapy
Reasonable Suspicion
Refractory
Serum
Sperm
Systemic Therapy
T Cell
Targeted Therapies
Tolerability
Trauma
Tubal Ligation
Tumor
Unstable Angina
Viral Load
Vitiligo
Warfarin
Washout

Semantics

Type Source Name
drug DRUGBANK Atezolizumab
disease MESH Skin Cancers
gene UNIPROT RPL17
gene UNIPROT PDCD1
gene UNIPROT CD274
disease MESH melanoma
disease DOID melanoma
pathway BSID Melanoma
disease MESH Merkel Cell Carcinoma
disease DOID Merkel Cell Carcinoma
drug DRUGBANK MCC
disease MESH Squamous Cell Carcinoma
disease DOID Squamous Cell Carcinoma
drug DRUGBANK Aspartame
gene UNIPROT CLEC4D
gene UNIPROT FH
gene UNIPROT SLC17A5
drug DRUGBANK Alkaline Phosphatase
disease MESH metastases
drug DRUGBANK Creatinine
drug DRUGBANK Heparin
drug DRUGBANK Warfarin
disease MESH opportunistic infections
disease MESH viral load
disease MESH Men
gene UNIPROT ELL
disease MESH Cancer
disease DOID Cancer
disease DOID skin cancer
gene UNIPROT AKR1A1
gene UNIPROT ARMC9
drug DRUGBANK Ipilimumab
gene UNIPROT BRAF
gene UNIPROT MAP2K7
drug DRUGBANK Talimogene laherparepvec
gene UNIPROT CYREN
disease MESH cardiovascular disease
disease MESH cardiac disease
disease MESH myocardial infarction
disease DOID myocardial infarction
disease MESH hypertension
disease DOID hypertension
disease MESH arrhythmia
disease MESH unstable angina
disease DOID unstable angina
disease MESH Type 2 diabetes mellitus
disease DOID Type 2 diabetes mellitus
disease MESH fasting
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK D-glucose
disease MESH diagnosis
disease MESH diseases metabolic
disease MESH complications
drug DRUGBANK Mitomycin
gene UNIPROT AES
disease MESH alopecia
disease DOID alopecia
disease MESH vitiligo
disease DOID vitiligo
disease DOID neuropathy
gene UNIPROT IL2
gene UNIPROT IL15
gene UNIPROT IL7
disease MESH hypersensitivity
disease DOID hypersensitivity
disease MESH growth
disease MESH spinal cord compression
disease MESH hypercalcemia
disease DOID hypercalcemia
drug DRUGBANK Denosumab
disease MESH autoimmune disease
disease DOID autoimmune disease
disease MESH systemic lupus erythematosus
disease DOID systemic lupus erythematosus
pathway BSID Systemic lupus erythematosus
disease MESH rheumatoid arthritis
disease DOID rheumatoid arthritis
pathway BSID Rheumatoid arthritis
disease MESH inflammatory bowel disease
disease DOID inflammatory bowel disease
disease MESH thrombosis
disease DOID thrombosis
disease MESH antiphospholipid syndrome
disease DOID antiphospholipid syndrome
disease MESH Guillain-Barre syndrome
disease DOID Guillain-Barre syndrome
disease MESH multiple sclerosis
disease DOID multiple sclerosis
disease MESH vasculitis
disease MESH vasculitis
disease DOID vasculitis
disease MESH glomerulonephritis
disease DOID glomerulonephritis
disease MESH hypothyroidism
disease DOID hypothyroidism
disease MESH Type 1 diabetes mellitus
disease DOID Type 1 diabetes mellitus
disease MESH eczema
disease DOID eczema
disease MESH psoriasis
disease DOID psoriasis
disease MESH lichen simplex chronicus
disease MESH psoriatic arthritis
disease DOID psoriatic arthritis
drug DRUGBANK Methionine
gene UNIPROT SLTM
gene UNIPROT MET
gene UNIPROT RNMT
disease DOID Rash
drug DRUGBANK Hydrocortisone
drug DRUGBANK Butyric Acid
drug DRUGBANK Desonide
drug DRUGBANK Methotrexate
drug DRUGBANK Prednisone
drug DRUGBANK Cyclophosphamide
drug DRUGBANK Azathioprine
drug DRUGBANK Thalidomide
gene UNIPROT TNF
drug DRUGBANK Dexamethasone
drug DRUGBANK Fluticasone
disease MESH chronic obstructive pulmonary disease
disease DOID chronic obstructive pulmonary disease
drug DRUGBANK Fludrocortisone
disease MESH orthostatic hypotension
disease MESH adrenal insufficiency
disease MESH idiopathic pulmonary fibrosis
disease DOID idiopathic pulmonary fibrosis
disease MESH pneumonitis
disease DOID pneumonia
disease MESH bronchiolitis obliterans
disease DOID bronchiolitis obliterans
disease MESH cryptogenic organizing pneumonia
disease DOID cryptogenic organizing pneumonia
disease MESH fibrosis
disease MESH hepatitis B
disease DOID hepatitis B
pathway BSID Hepatitis B
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
gene UNIPROT EHD1
disease MESH infection
disease MESH hepatitis C
disease DOID hepatitis C
pathway BSID Hepatitis C
disease MESH tuberculosis
disease DOID tuberculosis
pathway BSID Tuberculosis
disease MESH bacteremia
disease MESH urinary tract infection
disease DOID urinary tract infection
disease MESH Influenza
disease DOID Influenza
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH Carcinoma
disease DOID Carcinoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *